CRISPR 및 Cas 유전자 시장 규모와 예측(2021-2031년) : 세계 및 지역별 점유율, 동향, 성장 기회 분석 리포트 - 제품·서비스별, 용도별, 최종사용자별, 지역별
CRISPR and Cas Gene Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product & Service, Application, End User, and Geography
상품코드:1938273
리서치사:The Insight Partners
발행일:2026년 01월
페이지 정보:영문 318 Pages
라이선스 & 가격 (부가세 별도)
한글목차
CRISPR 및 Cas 유전자 시장 규모는 2024년 41억 3,000만 달러에서 2031년까지 180억 4,000만 달러로 성장할 것으로 예측됩니다. 2025-2031년 연평균 복합 성장률(CAGR) 23.4%를 나타낼 것으로 예측됩니다. 유전자 질환 증가 추세, 연구 자금 및 투자 확대, 정밀의료에 대한 수요 급증은 CRISPR 및 Cas 유전자 시장 규모 확대에 기여하는 두드러진 요인입니다. 또한, 차세대 편집 기술로의 진화로 인해 가까운 미래에 새로운 CRISPR 및 Cas 유전자 시장의 트렌드가 만들어질 것으로 예측됩니다.
CRISPR-Cas 유전자 편집 기술은 기존의 Cas9 뉴클레아제를 뛰어넘는 진화를 거듭하고 있습니다. 염기교정, 프라임 편집, RNA/후성유전체 편집과 같은 차세대 툴은 위험 부담 없이 높은 정확도를 구현하여 치료법 혁신을 주도하고 있습니다. 이러한 기술을 통해 알려진 질병 원인 돌연변이의 90%를 치료할 수 있습니다. David Liu 연구실이 개척한 베이스 편집 기술은 불활성화된 Cas9과 탈아미나제(deaminase)를 융합하여 C*G→T*A 또는 A*T→G*C 염기쌍으로의 변환을 실현합니다. Beam Therapeutics는 베이스 에디터를 사용하여 SCD를 표적으로 삼아 조혈모세포에서 최소한의 인델(삽입 및 결실)로 최대 80%의 교정 효율을 달성하고 있습니다.
프라임 에디팅은 Cas9 니카제와 역전사효소, 프라임 에디팅 가이드 RNA(pegRNA)를 결합하여 최대 44개 염기쌍에 걸친 DNA 영역의 삽입 및 결실과 같은 '검색 및 치환'형 수정을 가능하게 합니다. 2020년에는 프라임메디신의 기술이 낭포성 섬유증 치료에 있으며, 환자 유래 오가노이드내 기능적 수정이 가능함을 입증했습니다. 2025년 2월에는 희귀 대사질환을 대상으로 한 세계 최초 프라임 에디팅 인체 임상시험을 진행하여 50-70% 범위의 변형 효율을 보였습니다. 2025년 4월 현재 이러한 기법에 기반한 98건의 임상시험이 진행 중으로, 안전하고 범용성 높은 유전자 치료의 새로운 시대를 예고하고 있습니다. 차세대 유전자 편집 기술은 CRISPR 영역의 패러다임 전환을 시사하고 있으며, 이러한 혁신은 유전성 질환, 암, 감염성 질환에 대한 보다 안전하고 다양한 치료법을 약속하며 CRISPR 및 Cas 유전자 시장의 중요한 동향으로 부상하고 있습니다.
최종사용자별 인사이트
최종사용자별로 보면 CRISPR 및 Cas 유전자 시장은 생명공학 및 제약 기업, 학술 및 정부 연구기관, 위탁연구기관(CRO) 및 의약품 개발 및 제조 수탁기관(CDMO)으로 구분됩니다. 2024년 기준, 생명공학 및 제약 기업 부문이 가장 큰 시장 점유율을 차지했습니다. 이 부문의 성장은 CRISPR을 활용한 새로운 치료법 개발을 위한 임상 개발, 파트너십, 상업화에 대한 대규모 투자에 의해 주도되고 있습니다. 그 예로 Vertex Pharmaceuticals와 CRISPR Therapeutics가 공동 개발한 Casgevy(엑사감마글로겐 오토템셀)를 들 수 있습니다. 이는 겸상적혈구증 및 수혈 의존성 베타 지중해빈혈 치료에서 FDA가 승인한 최초의 CRISPR 매개 접근법입니다. 이 방법은 조혈모세포를 정밀하게 편집하여 환자에게 장기적인 이익을 가져다 줄 수 있습니다. 마찬가지로 인테리어 테라퓨틱스(Interior Therapeutics)와 같은 회사는 유전성 혈관성 부종에 대한 CRISPR 기반 생체내 접근 방식인 NTLA-2002를 2025년 임상 3상 시험에 진입하여 발작 빈도를 감소시킬 것으로 기대되는 결과를 얻었습니다. 다른 사례로는 Verve Therapeutics의 CTX-310 후보물질을 들 수 있습니다. 이는 ANGPTL3를 표적으로 하여 LDL 콜레스테롤과 중성지방 감소를 목표로 하고 있으며, 2025년 유망한 임상 1상 데이터를 기대하고 있습니다. 이러한 임상시험 증가와 승인의 진전은 맞춤형 의료에 대한 엄청난 수요, 유전성 질환의 발생률 증가, CRISPR 기술 개선을 위한 적절한 인수 활동 등의 요인으로 인해 이 분야도 성장하고 있음을 보여줍니다. 이를 통해 생명공학 기업 및 제약회사들이 차세대 유전자 치료의 선두주자가 되어 CRISPR 및 Cas 유전자 시장의 성장을 가속하고 있습니다.
목차
제1장 개요
제2장 CRISPR 및 Cas 유전자 시장의 시장 구도
제3장 경쟁 구도
제4장 CRISPR 및 Cas 유전자 시장 - 주요 시장 역학
제5장 CRISPR 및 Cas 유전자 시장 - 세계 시장 분석
제6장 CRISPR 및 Cas 유전자 시장 매출 분석 - 제품 및 서비스별
제7장 CRISPR 및 Cas 유전자 시장 매출 분석 - 용도별
제8장 CRISPR 및 Cas 유전자 시장 매출 분석 - 최종사용자별
제9장 CRISPR 및 Cas 유전자 시장 - 지역 분석
제10장 CRISPR 및 Cas 유전자 시장 업계 상황
제11장 CRISPR 및 Cas 유전자 시장 - 주요 기업 개요
제12장 추가 분석 대상 기업 리스트
제13장 부록
KSA
영문 목차
영문목차
The CRISPR and Cas gene market size is expected to grow from US$ 4.13 billion in 2024 to US$ 18.04 billion by 2031; it is projected to register a CAGR of 23.4% during 2025-2031. The rising prevalence of genetic disorders, growing research funding and investments, and surging demand for precision medicine are noteworthy factors contributing to the expansion of the CRISPR and Cas gene market size. Additionally, the evolution toward next-gen editing is projected to bring new CRISPR and Cas gene market trends in the near future.
The CRISPR-Cas gene editing landscape is evolving beyond traditional Cas9 nucleases. Next-generation tools such as base editing, prime editing, and RNA/epigenetic editing offer precision without such risks, driving therapeutic breakthroughs. These techniques can fix 90% of known disease-causing mutations. Base editing, pioneered by David Liu's lab, fuses a deactivated Cas9 with deaminases to convert C*G to T*A or A*T to G*C base pairs. Beam Therapeutics employs base editors to target SCD, achieving up to 80% correction efficiency in hematopoietic stem cells with minimal indels.
Prime editing combines the use of the Cas9 nickase with a reverse transcriptase and a prime editing guide RNA (pegRNA) to enable "search-and-replace" modification, such as insertions and deletions, of a DNA span extending to 44 bp. In 2020, Prime Medicine's technology demonstrated functional correction within patient organoids for the treatment of cystic fibrosis. In February 2025, it carried out first-in-human prime editing in a rare metabolic disorder and showed a modification efficiency ranging between 50%-70%. As of April 2025, there are 98 clinical trials based on these modalities that foretell a new age of safe and versatile gene therapies. The next generation of gene-editing technologies signals a paradigm shift within the CRISPR area. These innovations promise safer, more versatile therapies for genetic diseases, cancer, and infectious disorders, thereby emerging as a significant trend in the CRISPR and Cas gene market.
End User-Based Insights
Based on end user, the CRISPR and Cas gene market is segmented into biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations and CDMOs. The biotechnology and pharmaceutical companies segment held the largest CRISPR and Cas gene market share in 2024. The growth in this segment is driven by their massive investments in clinical development, partnerships, and commercialization to unlock new therapies using CRISPR. One such example is the collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics to create Casgevy (exagamglogene autotemcel), marking the first FDA-approved CRISPR-mediated approach to treating sickle cell disease and transfusion-dependent beta-thalassemia. This approach offers long-term patient benefits by precisely editing hematopoietic stem cells. Similarly, companies like Intellia Therapeutics moved their candidate, NTLA-2002, a CRISPR-based in vivo approach for hereditary angioedema, to a Phase 3 clinical trial in 2025, with encouraging reductions in attack rates. Other examples include Verve Therapeutics and their CTX-310 candidate, which aims to reduce LDL cholesterol and triglycerides by targeting ANGPTL3, with promising phase 1 clinical trial data expected in 2025. This increase in clinical trials and approval highlights that this segment is also witnessing growth driven by their huge requirements for personalized healthcare, increasing incidence rates for genetic disorders, and appropriate acquisition to improve CRISPR technology, making biotech and pharma giants leaders in next-generation gene therapies, thereby fueling the CRISPR and Cas gene market growth.
The World Health Organization and the FDA are among the primary and secondary sources referred to while preparing the CRISPR and Cas gene market report.
Table Of Contents
1. Executive Summary
1.1 Analyst Market Outlook
1.2 Market Attractiveness
2. CRISPR and Cas Gene Market Landscape
2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
2.3.1 List of Manufacturers/Suppliers
2.3.2 List of Potential Customers (Upto 50)
2.4 PEST Analysis
2.5 Impact of Artificial Intelligence (AI)
2.6 Product or Technology Roadmap
2.7 Sustainability and ESG Trends
2.8 Regulatory Framework
3. Competitive Landscape
3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2024 - By Key Players
3.3 Market Concentration
4. CRISPR and Cas Gene Market - Key Industry Dynamics
4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints
5. CRISPR and Cas Gene Market - Global Market Analysis
5.1 CRISPR and Cas Gene Market Revenue (US$ Million), 2021-2031
5.2 CRISPR and Cas Gene Market Forecast and Analysis
6. CRISPR and Cas Gene Market Revenue Analysis -Product And Service
6.1 CRISPR and Cas Gene Market Forecasts and Analysis by Product And Service
6.1.1 Product
6.1.1.1 Overview
6.1.1.2 Product: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
6.1.2 Services
6.1.2.1 Overview
6.1.2.2 Services: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
7. CRISPR and Cas Gene Market Revenue Analysis -Application
7.1 CRISPR and Cas Gene Market Forecasts and Analysis by Application
7.1.1 Biomedical
7.1.1.1 Overview
7.1.1.2 Biomedical: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
7.1.2 Agriculture
7.1.2.1 Overview
7.1.2.2 Agriculture: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
8. CRISPR and Cas Gene Market Revenue Analysis -End User
8.1 CRISPR and Cas Gene Market Forecasts and Analysis by End User
8.1.1 Biotechnology and Pharmaceutical Companies
8.1.1.1 Overview
8.1.1.2 Biotechnology and Pharmaceutical Companies: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
8.1.2 Academics and Government Research Institutes
8.1.2.1 Overview
8.1.2.2 Academics and Government Research Institutes: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
8.1.3 Contract Research Organizations (CRO) and CDMOs
8.1.3.1 Overview
8.1.3.2 Contract Research Organizations (CRO) and CDMOs: CRISPR and Cas Gene Market -Revenue, 2021-2031 (US$ Million)
9. CRISPR and Cas Gene Market - Geographical Analysis
9.1 North America
9.1.1 North America CRISPR and Cas Gene Market Overview
9.1.2 North America: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.1.3 North America: CRISPR and Cas Gene Market- By Segmentation
9.1.3.1 Product And Service
9.1.3.2 Product For Product And Service
9.1.3.3 Services For Product And Service
9.1.3.4 Application
9.1.3.5 Biomedical For Application
9.1.3.6 End User
9.1.4 North America: CRISPR and Cas Gene Market Breakdown by Countries
9.1.4.1 United States Market
9.1.4.1.1 United States: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.1.4.1.2 United States: CRISPR and Cas Gene Market- By Segmentation
9.1.4.1.2.1 Product And Service
9.1.4.1.2.2 Product For Product And Service
9.1.4.1.2.3 Services For Product And Service
9.1.4.1.2.4 Application
9.1.4.1.2.5 Biomedical For Application
9.1.4.1.2.6 End User
9.1.4.2 Canada Market
9.1.4.2.1 Canada: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.1.4.2.2 Canada: CRISPR and Cas Gene Market- By Segmentation
9.1.4.2.2.1 Product And Service
9.1.4.2.2.2 Product For Product And Service
9.1.4.2.2.3 Services For Product And Service
9.1.4.2.2.4 Application
9.1.4.2.2.5 Biomedical For Application
9.1.4.2.2.6 End User
9.1.4.3 Mexico Market
9.1.4.3.1 Mexico: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.1.4.3.2 Mexico: CRISPR and Cas Gene Market- By Segmentation
9.1.4.3.2.1 Product And Service
9.1.4.3.2.2 Product For Product And Service
9.1.4.3.2.3 Services For Product And Service
9.1.4.3.2.4 Application
9.1.4.3.2.5 Biomedical For Application
9.1.4.3.2.6 End User
9.2 Europe
9.2.1 Europe CRISPR and Cas Gene Market Overview
9.2.2 Europe: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.3 Europe: CRISPR and Cas Gene Market- By Segmentation
9.2.3.1 Product And Service
9.2.3.2 Product For Product And Service
9.2.3.3 Services For Product And Service
9.2.3.4 Application
9.2.3.5 Biomedical For Application
9.2.3.6 End User
9.2.4 Europe: CRISPR and Cas Gene Market Breakdown by Countries
9.2.4.1 United Kingdom Market
9.2.4.1.1 United Kingdom: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.4.1.2 United Kingdom: CRISPR and Cas Gene Market- By Segmentation
9.2.4.1.2.1 Product And Service
9.2.4.1.2.2 Product For Product And Service
9.2.4.1.2.3 Services For Product And Service
9.2.4.1.2.4 Application
9.2.4.1.2.5 Biomedical For Application
9.2.4.1.2.6 End User
9.2.4.2 Germany Market
9.2.4.2.1 Germany: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.4.2.2 Germany: CRISPR and Cas Gene Market- By Segmentation
9.2.4.2.2.1 Product And Service
9.2.4.2.2.2 Product For Product And Service
9.2.4.2.2.3 Services For Product And Service
9.2.4.2.2.4 Application
9.2.4.2.2.5 Biomedical For Application
9.2.4.2.2.6 End User
9.2.4.3 France Market
9.2.4.3.1 France: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.4.3.2 France: CRISPR and Cas Gene Market- By Segmentation
9.2.4.3.2.1 Product And Service
9.2.4.3.2.2 Product For Product And Service
9.2.4.3.2.3 Services For Product And Service
9.2.4.3.2.4 Application
9.2.4.3.2.5 Biomedical For Application
9.2.4.3.2.6 End User
9.2.4.4 Italy Market
9.2.4.4.1 Italy: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.4.4.2 Italy: CRISPR and Cas Gene Market- By Segmentation
9.2.4.4.2.1 Product And Service
9.2.4.4.2.2 Product For Product And Service
9.2.4.4.2.3 Services For Product And Service
9.2.4.4.2.4 Application
9.2.4.4.2.5 Biomedical For Application
9.2.4.4.2.6 End User
9.2.4.5 Spain Market
9.2.4.5.1 Spain: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.4.5.2 Spain: CRISPR and Cas Gene Market- By Segmentation
9.2.4.5.2.1 Product And Service
9.2.4.5.2.2 Product For Product And Service
9.2.4.5.2.3 Services For Product And Service
9.2.4.5.2.4 Application
9.2.4.5.2.5 Biomedical For Application
9.2.4.5.2.6 End User
9.2.4.6 Rest of Europe Market
9.2.4.6.1 Rest of Europe: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.2.4.6.2 Rest of Europe: CRISPR and Cas Gene Market- By Segmentation
9.2.4.6.2.1 Product And Service
9.2.4.6.2.2 Product For Product And Service
9.2.4.6.2.3 Services For Product And Service
9.2.4.6.2.4 Application
9.2.4.6.2.5 Biomedical For Application
9.2.4.6.2.6 End User
9.3 Asia Pacific
9.3.1 Asia Pacific CRISPR and Cas Gene Market Overview
9.3.2 Asia Pacific: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.3 Asia Pacific: CRISPR and Cas Gene Market- By Segmentation
9.3.3.1 Product And Service
9.3.3.2 Product For Product And Service
9.3.3.3 Services For Product And Service
9.3.3.4 Application
9.3.3.5 Biomedical For Application
9.3.3.6 End User
9.3.4 Asia Pacific: CRISPR and Cas Gene Market Breakdown by Countries
9.3.4.1 China Market
9.3.4.1.1 China: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.4.1.2 China: CRISPR and Cas Gene Market- By Segmentation
9.3.4.1.2.1 Product And Service
9.3.4.1.2.2 Product For Product And Service
9.3.4.1.2.3 Services For Product And Service
9.3.4.1.2.4 Application
9.3.4.1.2.5 Biomedical For Application
9.3.4.1.2.6 End User
9.3.4.2 Japan Market
9.3.4.2.1 Japan: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.4.2.2 Japan: CRISPR and Cas Gene Market- By Segmentation
9.3.4.2.2.1 Product And Service
9.3.4.2.2.2 Product For Product And Service
9.3.4.2.2.3 Services For Product And Service
9.3.4.2.2.4 Application
9.3.4.2.2.5 Biomedical For Application
9.3.4.2.2.6 End User
9.3.4.3 India Market
9.3.4.3.1 India: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.4.3.2 India: CRISPR and Cas Gene Market- By Segmentation
9.3.4.3.2.1 Product And Service
9.3.4.3.2.2 Product For Product And Service
9.3.4.3.2.3 Services For Product And Service
9.3.4.3.2.4 Application
9.3.4.3.2.5 Biomedical For Application
9.3.4.3.2.6 End User
9.3.4.4 Australia Market
9.3.4.4.1 Australia: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.4.4.2 Australia: CRISPR and Cas Gene Market- By Segmentation
9.3.4.4.2.1 Product And Service
9.3.4.4.2.2 Product For Product And Service
9.3.4.4.2.3 Services For Product And Service
9.3.4.4.2.4 Application
9.3.4.4.2.5 Biomedical For Application
9.3.4.4.2.6 End User
9.3.4.5 South Korea Market
9.3.4.5.1 South Korea: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.4.5.2 South Korea: CRISPR and Cas Gene Market- By Segmentation
9.3.4.5.2.1 Product And Service
9.3.4.5.2.2 Product For Product And Service
9.3.4.5.2.3 Services For Product And Service
9.3.4.5.2.4 Application
9.3.4.5.2.5 Biomedical For Application
9.3.4.5.2.6 End User
9.3.4.6 Rest of APAC Market
9.3.4.6.1 Rest of APAC: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.3.4.6.2 Rest of APAC: CRISPR and Cas Gene Market- By Segmentation
9.3.4.6.2.1 Product And Service
9.3.4.6.2.2 Product For Product And Service
9.3.4.6.2.3 Services For Product And Service
9.3.4.6.2.4 Application
9.3.4.6.2.5 Biomedical For Application
9.3.4.6.2.6 End User
9.4 Middle East and Africa
9.4.1 Middle East and Africa CRISPR and Cas Gene Market Overview
9.4.2 Middle East and Africa: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.4.3 Middle East and Africa: CRISPR and Cas Gene Market- By Segmentation
9.4.3.1 Product And Service
9.4.3.2 Product For Product And Service
9.4.3.3 Services For Product And Service
9.4.3.4 Application
9.4.3.5 Biomedical For Application
9.4.3.6 End User
9.4.4 Middle East and Africa: CRISPR and Cas Gene Market Breakdown by Countries
9.4.4.1 Saudi Arabia Market
9.4.4.1.1 Saudi Arabia: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.4.4.1.2 Saudi Arabia: CRISPR and Cas Gene Market- By Segmentation
9.4.4.1.2.1 Product And Service
9.4.4.1.2.2 Product For Product And Service
9.4.4.1.2.3 Services For Product And Service
9.4.4.1.2.4 Application
9.4.4.1.2.5 Biomedical For Application
9.4.4.1.2.6 End User
9.4.4.2 South Africa Market
9.4.4.2.1 South Africa: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.4.4.2.2 South Africa: CRISPR and Cas Gene Market- By Segmentation
9.4.4.2.2.1 Product And Service
9.4.4.2.2.2 Product For Product And Service
9.4.4.2.2.3 Services For Product And Service
9.4.4.2.2.4 Application
9.4.4.2.2.5 Biomedical For Application
9.4.4.2.2.6 End User
9.4.4.3 United Arab Emirates Market
9.4.4.3.1 United Arab Emirates: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.4.4.3.2 United Arab Emirates: CRISPR and Cas Gene Market- By Segmentation
9.4.4.3.2.1 Product And Service
9.4.4.3.2.2 Product For Product And Service
9.4.4.3.2.3 Services For Product And Service
9.4.4.3.2.4 Application
9.4.4.3.2.5 Biomedical For Application
9.4.4.3.2.6 End User
9.4.4.4 Rest of Middle East and Africa Market
9.4.4.4.1 Rest of Middle East and Africa: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.4.4.4.2 Rest of Middle East and Africa: CRISPR and Cas Gene Market- By Segmentation
9.4.4.4.2.1 Product And Service
9.4.4.4.2.2 Product For Product And Service
9.4.4.4.2.3 Services For Product And Service
9.4.4.4.2.4 Application
9.4.4.4.2.5 Biomedical For Application
9.4.4.4.2.6 End User
9.5 South and Central America
9.5.1 South and Central America CRISPR and Cas Gene Market Overview
9.5.2 South and Central America: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.5.3 South and Central America: CRISPR and Cas Gene Market- By Segmentation
9.5.3.1 Product And Service
9.5.3.2 Product For Product And Service
9.5.3.3 Services For Product And Service
9.5.3.4 Application
9.5.3.5 Biomedical For Application
9.5.3.6 End User
9.5.4 South and Central America: CRISPR and Cas Gene Market Breakdown by Countries
9.5.4.1 Brazil Market
9.5.4.1.1 Brazil: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.5.4.1.2 Brazil: CRISPR and Cas Gene Market- By Segmentation
9.5.4.1.2.1 Product And Service
9.5.4.1.2.2 Product For Product And Service
9.5.4.1.2.3 Services For Product And Service
9.5.4.1.2.4 Application
9.5.4.1.2.5 Biomedical For Application
9.5.4.1.2.6 End User
9.5.4.2 Argentina Market
9.5.4.2.1 Argentina: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.5.4.2.2 Argentina: CRISPR and Cas Gene Market- By Segmentation
9.5.4.2.2.1 Product And Service
9.5.4.2.2.2 Product For Product And Service
9.5.4.2.2.3 Services For Product And Service
9.5.4.2.2.4 Application
9.5.4.2.2.5 Biomedical For Application
9.5.4.2.2.6 End User
9.5.4.3 Rest of South and Central America Market
9.5.4.3.1 Rest of South and Central America: CRISPR and Cas Gene Market Revenue and Forecasts, 2021-2031 (US$ Million)
9.5.4.3.2 Rest of South and Central America: CRISPR and Cas Gene Market- By Segmentation
9.5.4.3.2.1 Product And Service
9.5.4.3.2.2 Product For Product And Service
9.5.4.3.2.3 Services For Product And Service
9.5.4.3.2.4 Application
9.5.4.3.2.5 Biomedical For Application
9.5.4.3.2.6 End User
10. CRISPR and Cas Gene Market Industry Landscape
11. CRISPR and Cas Gene Market - Key Company Profiles
